Adjuvancy and reactogenicity of N-acetylglycosaminyl-N-acetylmuramyl-dipeptide (GMDP) orally administered just prior to trivalent influenza subunit vaccine. A double-blind placebo-controlled study in nursing home residents.
October 1996
Article
volume 14, issue 14 pp 1327-1330.
| Related Files |
|---|
View PDF Version
(eur_osterhaus_9153.pdf, 0.4MB) |
|
Redirect to publisher's version
(publisher's version.url.txt, 51 bytes) |
One hundred and fifty-three nursing home residents received 0, 5, 25 or 50 mg N-acetylglucosaminyl-N-acetylmuramyl-dipeptide (GMDP) orally, and trivalent influenza subunit vaccine intramuscularly. One day after intervention, there was a strong increase of total leucocytes, monocytes and neutrophils in the groups receiving 25 or 50 mg GMDP. A GMDP dose dependent increase in systemic, but not in local, vaccine side-effects was observed. No significant differences in post-vaccination haemagglutination inhibiting serum antibody titres were observed between the four groups, indicating that oral administration of GMDP together with influenza vaccination, does not lead to a higher vaccine efficacy.
Keywords
- Male
- Human
- Female
- Placebos
- Dose-Response Relationship, Immunologic
- Administration, Oral
- Nursing Homes
- Double-Blind Method
- 0 (Antibodies, Viral)
- 0 (Influenza Vaccine)
- 0 (Adjuvants, Immunologic)
- Antibodies, Viral/biosynthesis/blood
- 0 (Placebos)
- Adjuvants, Immunologic/administration & dosage/pharmacology/*therapeutic
- Influenza Vaccine/*administration & dosage/adverse effects
- use
Automatically Extracted Terms
- vaccine
- influenza
- study
- subject
- 50 mg gmdp
- side-effects
- influenza vaccine
- nursing home residents
- number
- intervention
- vaccination
- variable
- symptom
- titre
- post-vaccination
- 4 weeks
- resident
- nursing
- group
- table
